CLRB's Aroon Indicator triggered a bullish signal on July 27, 2022. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 122 similar instances where the Aroon Indicator showed a similar pattern. In 108 of the 122 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 63 cases where CLRB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 05, 2022. You may want to consider a long position or call options on CLRB as a result. In of 102 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for CLRB just turned positive on August 05, 2022. Looking at past instances where CLRB's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .
CLRB moved above its 50-day moving average on August 03, 2022 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CLRB crossed bullishly above the 50-day moving average on July 11, 2022. This indicates that the trend has shifted higher and could be considered a buy signal. In of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CLRB advanced for three days, in of 224 cases, the price rose further within the following month. The odds of a continued upward trend are .
The 10-day RSI Indicator for CLRB moved out of overbought territory on July 22, 2022. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLRB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
CLRB broke above its upper Bollinger Band on July 19, 2022. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLRB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.224) is normal, around the industry mean (26.217). P/E Ratio (0.000) is within average values for comparable stocks, (100.146). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.703). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (316.522).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLRB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
|Technical Analysis||# Of Indicators||Avg. Odds|
a biopharmaceutical company that is engaged in developing compounds for the treatment and imaging of cancer
A.I.dvisor indicates that over the last year, CLRB has been loosely correlated with PDSB. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if CLRB jumps, then PDSB could also see price increases.
|PDSB - CLRB|
|ASMB - CLRB|
|MBRX - CLRB|
|ADPT - CLRB|
|MORF - CLRB|